Partner David Rosen was quoted in an Inside Health Policy article on January 22, 2014 titled “Generic Drug Industry Prioritizes Challenge to New Labeling Rule in 2014.” The article discusses the top priority for the generic drug industry in 2014 which will be combating a new regulation aimed at requiring generic drugmakers to make labeling changes to reflect new safety information. Rosen was quoted saying, “I think it’s going to be a pretty big deal.”
People
Related News
16 May 2025
In the News
Foley's East Coast Litigation Additions Highlighted in Legal Press
Foley & Lardner LLP partners Kenneth Breen, Phara Guberman, and Joseph Dowdy are featured across legal press for their recent move to the firm.
16 May 2025
In the News
Foley Attorneys Assess AI Use in Clinical Trials
Foley & Lardner LLP partners Monica Chmielewski and Kyle Faget shared insights on the growing adoption of artificial intelligence in clinical trials in the Clinical Trials Arena article, "Are regulators keeping pace with AI adoption in clinical trials?"
15 May 2025
In the News
Grace Fucci Publishes on Sustainability in Luxury Fashion
Foley & Lardner LLP associate Grace Fucci explores the intersection of luxury fashion and sustainability in The Global Legal Post article, "Can luxury fashion houses join the sustainability discussion?"